SCHEMBL6367461

SCHEMBL6367461

CCCCC(=Cc1ccc(F)cc1)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 6/20 0.54
TRPA1 O75762 2/20 0.52
PTGES O14684 5/20 0.52
PPARG P37231 4/20 0.52
HTR7 P34969 1/20 0.51
PSEN1 P49768 1/20 0.47
LMNA P02545 2/20 0.46
MEN1 O00255 1/20 0.46
CYP1A2 P05177 1/20 0.46
MAPT P10636 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
KMT2A Q03164 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HPGD P15428 1/20 0.45
APEX1 P27695 1/20 0.43
PTGS2 P35354 2/20 0.43
PTGS1 P23219 1/20 0.43
ALDH1A1 P00352 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1322605 0.85 ALOX5 (0.52) ALOX5PTGESPPARGLMNACYP2C9
SCHEMBL5607169 0.85 ALOX5 (0.52) ALOX5PTGESPPARGLMNAHPGD
SCHEMBL29741641 0.85 ALOX5 (0.52) ALOX5PTGESPPARGLMNAHPGD
SCHEMBL8702152 0.85 ALOX5 (0.59) ALOX5PTGESPPARGLMNAMEN1
SCHEMBL1786246 0.85 ALOX5 (0.59) ALOX5PTGESPPARGLMNAMEN1
SCHEMBL524131 0.85 ALOX5 (0.59) ALOX5PTGESPPARGLMNAMEN1
SCHEMBL524132 0.85 ALOX5 (0.59) ALOX5PTGESPPARGLMNAMEN1
SCHEMBL6060200 0.83 ALOX5 (0.49) ALOX5TRPA1PTGESPPARGPSEN1
SCHEMBL4662670 0.83 MEN1 (0.51) TRPA1PPARGLMNAMEN1CYP1A2
SCHEMBL4662669 0.83 MEN1 (0.51) TRPA1PPARGLMNAMEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050010068-A1 Use of microencapsulated transition metal reagents for reactions in supercritical fluids AVECIA LIMITED (GB) 2005-01-13 US disclosed
EP-1453780-A1 THE USE OF MICROENCAPSULATED TRANSITION METAL REAGENTS FOR REACTIONS IN SUPERCRITICAL FLUIDS Avecia Limited (GB) 2004-09-08 EP disclosed
WO-2003048090-A1 THE USE OF MICROENCAPSULATED TRANSITION METAL REAGENTS FOR REACTIONS IN SUPERCRITICAL FLUIDS AVECIA LIMITED (GB) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050010068-A1 Use of microencapsulated transition metal reagents for reactions in supercritical fluids HPSE, SIK1, SGK1 ALOX5 503/4885TRPA1 4170/4885PTGES 350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.